



Department of Pharmaceuticals  
Ministry of Chemicals and Fertilizers  
Government of India



Confederation of Indian Industry

## 15<sup>th</sup> CII National Pharmaceutical Conclave 2018

**"Expanding horizons of Pharmaceutical Industry: Embracing Accessibility, Affordability and Competitiveness"**

Monday; 19 November 2018: Hotel Le Meridien, New Delhi

### PROGRAM GRID

0830-1000 Hrs	Registration and Tea/ Coffee
1000-1045 Hrs	<b>Inaugural Session</b>
1045-1100 Hrs	Networking Tea
1100- 1215 Hrs	<b>Panel Discussion I: Ayushman Bharat- A New Era in Healthcare</b> <i>India is all set to enter a new paradigm of healthcare. The launch of Ayushman Bharat has laid down an ambitious framework and is poised to turn India into the largest pharmaceutical manufacturer of the World in about three years. With the successful launch of Ayushman Bharat programme, the Indian pharmaceutical industry needs to gear up to meet the demands of the most pioneering program of the Government of India. The Session would aim to define the actionable strategies and the role that pharmaceutical industry would play towards ensuring the success of this programme.</i>
1215-1235 Hrs	<b>Presentation: Department of Heavy Water Board</b> <i>Today, India is the largest producer of heavy water and the only country which has mastered multiple processes for its production. Heavy Water Board has been instrumental in developing new, breakthrough technologies for large scale production of heavy water thereby achieving self-reliance. Heavy water finds numerous applications in life science including metabolism studies, drug discovery and deuterated drugs/ APIs. Deuterated APIs offer various advantages such as sustained release, lower dose requirement, improved pharmacokinetic and toxicological properties and improved efficacy.</i>
1235- 1330 Hrs	Networking Lunch
1330- 1430 Hrs	<b>Panel Discussion II: Indian Bulk Drug Industry- Regaining the Lost Glory</b> <i>With every passing decade since 1970, India's pharmaceutical industry has gone from strength to strength in terms of broadening of scope, to deepening its prowess across the industry value chain. However, over the last decade, India has observed increased dependence on imports of many basic intermediates and APIs. From 2004 to 2016, the import of APIs has risen at a CAGR of 11 per cent. The dependency of API imports specifically from China has been a cause of major concern for industry and government. The current scenario demands a need to build a conducive ecosystem and increased competitiveness to build self-sufficiency in API manufacturing, as well as secure our pharma supply chain.</i>
1430 – 1500 Hrs	<b>Presentation: Capacity building in pharma sector through innovative PPP models</b> <i>Pharmaceutical companies in an expansion mode demand greater need for technically skilled and knowledgeable manpower. Varied skills are needed to cater to every aspect of the pharmaceutical value chain. The presentations would aim to share perspectives on creation of innovative PPP models for strengthening the pharmaceutical industry. Ways to boost capacity for churning out skilled professional who can add value across the value chain including regulatory, quality and compliance areas needs to be devised.</i>
1500- 1515 Hrs	Networking Tea
1515-1615 Hrs	<b>Panel Discussion III: Positioning India as a High Quality Global Manufacturing Hub for the Pharmaceutical Sector</b> <i>Aligned with the Make in India vision, Indian pharmaceutical industry is undergoing remarkable</i>



Department of Pharmaceuticals  
Ministry of Chemicals and Fertilizers  
Government of India



Confederation of Indian Industry

## 15<sup>th</sup> CII National Pharmaceutical Conclave 2018

*"Expanding horizons of Pharmaceutical Industry: Embracing Accessibility, Affordability and Competitiveness"*

Monday; 19 November 2018: Hotel Le Meridien, New Delhi

	<p>change and adapting to the shifting dynamics of global consumer markets. With 20% of the global export volume share of generic medicines, India is known as 'pharmacy of the world' and is working towards building its brand as the 'high quality'. While significant progress has been made on the quality front, India still needs to accelerate infrastructure upgrade, shift the weight of quality from getting the product right to getting the process right consistently, invest in building capabilities to make quality culture a 'way of life', and match the global regulatory standards to gain leadership in end-to-end drug manufacture.</p>
1615-1730 Hrs	<p><b>Panel Discussion IV: Ease of Doing Business in Pharmaceuticals in "Make in India" Era</b></p> <p>There has been a sustained growth in the pharmaceutical sector in India and is expected to grow at ~15 per cent in the next five years. While there has been a significant improvement in India's ranking in EoDB, there is a long way to go in order to achieve India's aim of being counted amongst the 50 countries that are leading in implementing the concept. The Government of India has initiated several initiatives to not only create a conducive business environment by streamlining regulatory structures, but also an investor-friendly business climate for EoDB to flourish in India. The Session aims to identify potential steps/ changes that needs to be taken so that India shapes into one of the most favored destinations globally for pharmaceutical investments.</p>
1730 Hrs	<p>Conclave Ends</p>